Supporting Information Fig 10. MT 63-78 enhances the growth inhibitory effect of AR signaling inhibitors in CRPC cells.

Relative growth of CL1 cells, following 3-day treatment with MT 63-78 (MT) alone or in combination with bicalutamide (Bic), MDV3100 (MDV), abiraterone (Abi) at the indicated concentrations. Results are expressed as means ±SD of three independent samples. One-way ANOVA test, followed by Tukey’s post hoc test for multiple comparisons was performed. Adjusted p values were calculated (Bicalutamide: \( \ast p=0.013 \) MT vs MT+ Bic 20uM; \( \ast\ast\ast p=8.09E-06 \) MT vs MT+ Bic 40uM; \( \ast\ast\ast\ast p=4.29E-05 \) Bic 20uM vs MT+ Bic 20uM; \( \ast\ast\ast\ast p=0.0023 \) Bic 40uM vs MT+ Bic 40uM. MDV3100: \( \ast\ast p=0.0071 \) MT vs MT+ MDV3100 20uM; \( \ast\ast\ast p=8.09E-06 \) MT vs MT+ MDV3100 40uM; \( \ast\ast\ast\ast p=3.02E-06 \) MDV3100 20uM vs MT+ MDV3100 20uM; \( \ast\ast\ast\ast p=0.0001 \) MDV3100 40uM vs MT+ MDV3100 40uM. Abiraterone: \( \ast p=0.00317 \) MT vs MT+ Abi; \( \ast\ast\ast p=0.0001 \) Abi vs MT+ Abi).